X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (163) 163
Publication (7) 7
Book Review (3) 3
Patent (3) 3
Book Chapter (2) 2
Book / eBook (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (95) 95
index medicus (71) 71
male (65) 65
oncology (52) 52
female (51) 51
middle aged (50) 50
aged (43) 43
adult (39) 39
cancer (38) 38
aged, 80 and over (24) 24
chemotherapy (23) 23
care and treatment (19) 19
treatment outcome (17) 17
metastasis (16) 16
prostate cancer (16) 16
research (16) 16
survival (16) 16
prognosis (15) 15
neoplasm metastasis (14) 14
obesity (13) 13
analysis (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
bortezomib (12) 12
cell biology (12) 12
health aspects (12) 12
risk factors (12) 12
young adult (12) 12
antineoplastic agents - administration & dosage (11) 11
cancer research (11) 11
expression (11) 11
prostatic neoplasms - pathology (11) 11
retrospective studies (11) 11
survival analysis (11) 11
urology & nephrology (11) 11
adolescent (10) 10
antineoplastic agents - therapeutic use (10) 10
breast cancer (10) 10
development and progression (10) 10
disease-free survival (10) 10
drug therapy (10) 10
medicine & public health (10) 10
neoplasms. tumors. oncology. including cancer and carcinogens (10) 10
patients (10) 10
physiological aspects (10) 10
disease progression (9) 9
medicine (9) 9
proteins (9) 9
angiogenesis (8) 8
cancer therapies (8) 8
child (8) 8
hospitals (8) 8
kinases (8) 8
medical prognosis (8) 8
multivariate analysis (8) 8
studies (8) 8
therapy (8) 8
ubiquitin (8) 8
ubiquitin-proteasome system (8) 8
animals (7) 7
antineoplastic agents - adverse effects (7) 7
cell line, tumor (7) 7
chemotherapy, adjuvant (7) 7
clinical trials (7) 7
drug administration schedule (7) 7
endocrinology & metabolism (7) 7
follow-up studies (7) 7
hematology, oncology and palliative medicine (7) 7
medicine, research & experimental (7) 7
neoplasm staging (7) 7
proportional hazards models (7) 7
proteasome endopeptidase complex - metabolism (7) 7
time factors (7) 7
tumor cells, cultured (7) 7
adenocarcinoma (6) 6
adolescents (6) 6
antimitotic agents (6) 6
antineoplastic agents (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
apoptosis (6) 6
biomarkers (6) 6
biomedicine (6) 6
body mass index (6) 6
bone neoplasms - secondary (6) 6
boronic acids - pharmacology (6) 6
breast neoplasms - drug therapy (6) 6
cancer patients (6) 6
case report (6) 6
cell cycle (6) 6
diagnosis (6) 6
diet (6) 6
down-regulation (6) 6
efficacy (6) 6
endothelial growth-factor (6) 6
epidemiology (6) 6
gene expression (6) 6
genetics (6) 6
glioma (6) 6
greece (6) 6
immunohistochemistry (6) 6
kaplan-meier estimate (6) 6
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BMC Cancer, ISSN 1471-2407, 07/2014, Volume 14, Issue 1, pp. 515 - 515
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 7/2016, Volume 158, Issue 2, pp. 307 - 321
Journal Article
World Journal of Urology, ISSN 0724-4983, 3/2017, Volume 35, Issue 3, pp. 411 - 419
Journal Article
Journal Article
Journal of Neuro-Oncology, ISSN 0167-594X, 9/2017, Volume 134, Issue 2, pp. 443 - 451
Small molecules, mainly tyrosine kinase inhibitors, are currently used in various malignancies. Lapatinib, a dual inhibitor of EGFR/HER2 tyrosine kinases, has... 
Neurology | Medicine & Public Health | Non-small cell lung cancer | Oncology | Brain metastases | Breast cancer | Lapatinib | Whole brain radiotherapy | PROGNOSTIC VALUE | EGFR | CHEMOTHERAPY | CLINICAL NEUROLOGY | RADIATION-THERAPY | TEMOZOLOMIDE | CAPECITABINE | ONCOLOGY | GW572016 | GROWTH | TYROSINE KINASE INHIBITOR | CLINICAL ACTIVITY | Brain - diagnostic imaging | Chemoradiotherapy - adverse effects | Follow-Up Studies | Brain Neoplasms - diagnostic imaging | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Breast Neoplasms - therapy | Brain Neoplasms - secondary | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Carcinoma, Non-Small-Cell Lung - pathology | Treatment Outcome | Brain - radiation effects | Lung Neoplasms - therapy | Disease Progression | Brain - drug effects | Carcinoma, Non-Small-Cell Lung - therapy | Breast Neoplasms - pathology | Quinazolines - therapeutic use | Brain Neoplasms - therapy | Quinazolines - adverse effects | Aged | Tyrosine | Brain | Care and treatment | Oncology, Experimental | Clinical trials | Lung cancer, Small cell | Metastasis | Research | Lung cancer, Non-small cell | Antineoplastic agents | Radiotherapy | Antimitotic agents | Analysis | Cancer | Dexamethasone | Epidermal growth factor receptors | Toxicity | Lung cancer | Non-small cell lung carcinoma | Radiation therapy | ErbB-2 protein | Metastases | Magnetic resonance imaging | Cell lines | Protein-tyrosine kinase
Journal Article
BMC Cancer, ISSN 1471-2407, 06/2012, Volume 12, Issue 1, pp. 271 - 271
Background: The aim was to compare two standard chemotherapy regimens combined with bevacizumab as first-line treatment in patients with metastatic colorectal... 
Irinotecan | Chemotherapy | Capecitabine | Angiogenic markers | Colorectal cancer | Bevacizumab | COLON-CANCER | OSTEOPONTIN | ONCOLOGY | NITRIC-OXIDE | ORAL FLUOROPYRIMIDINES | BICC-C | EXPRESSION | CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | Osteopontin - blood | Leucovorin - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - administration & dosage | Neoplasm Metastasis | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Treatment Outcome | Biomarkers - blood | Angiogenic Proteins - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Care and treatment | Patient outcomes | Research | Comparative analysis | Cancer | Clinical trials | Leucovorin | Metastasis | Antineoplastic agents | Antimitotic agents | Cancer patients | Nitric oxide | Product development | Vascular endothelial growth factor | Growth factors
Journal Article
Frontiers in Oncology, ISSN 2234-943X, 2015, Volume 5, p. 6
Neuroendocrine prostate carcinoma, either co-present with the local adenocarcinoma disease or as a result of transdifferentiation later in time, was described... 
Small cell prostate carcinoma | Androgen-independent | Neuroendocrine prostate cancer | Castration-resistant | Targeted therapy | Androgen independent | targeted therapy | neuroendocrine prostate cancer | small cell prostate carcinoma
Journal Article
Annals of oncology, ISSN 0923-7534, 2013, Volume 24, Issue 5, pp. 1141 - 1162
Journal Article
by Martin, Miguel and Holmes, Frankie A and Ejlertsen, Bent and Delaloge, Suzette and Moy, Beverly and Iwata, Hiroji and von Minckwitz, Gunter and Chia, Stephen K L and Mansi, Janine and Barrios, Carlos H and Gnant, Michael and Tomašević, Zorica and Denduluri, Neelima and Šeparović, Robert and Gokmen, Erhan and Bashford, Anna and Ruiz Borrego, Manuel and Kim, Sung-Bae and Kim, Seung Jin and Jakobsen, Erik Hugger and Ciceniene, Audrone and Inoue, Kenichi and Overkamp, Friedrich and Heijns, Joan B and Armstrong, Anne C and Link, John S and Joy, Anil Abraham and Bryce, Richard and Wong, Alvin and Moran, Susan and Yao, Bin and Xu, Feng and Xu, Binghe and Auerbach, Alan and Buyse, Marc and Chan, Arlene and Harvey, Vernon and Tomek, Rudolf and Robert, Nicholas J and Gore, Ira and Smith, John W and Smith, Julie C and Masuda, Norikazu and Di Sean Kendall, S and Harker, William Graydon and Petrakova, Katarina and Guerrero Zotano, Angel and Simon, Amparo Ruiz and Konstantinovic, Zora Neskovic and Iannotti, Nicholas O and Tassone, Pierfrancesco and Rodriguez, Gladys I and Jáñez Martinez, Noelia and Crespo Massieu, Carmen and Smickoska, Snezana and Somali, Isil and Yilmaz, Ugur and Alonso, Mirta Garcia and Rosales, Adolfo Murias and Cold, Soeren and Knoop, Ann Soegaard and Patt, Debra and Hellerstedt, Beth A and Morales Murillo, Serafin and Mayer, Ingrid A and Means-Powell, Julie Ann and Hui, Rina and Senecal, Francis M and De Boer, Richard Hendry and Shen, Zhenzhou and Luczak, Adam Andrzej and Chui, Joanna W.Y and Chui, Stephen and Tsang, Janice Wing-hang and Lang, Istvan and Rai, Yoshiaki and Hozumi, Yasuo and Ten Tije, Albert J and Bhandari, Manish and Osborne, Cynthia R.C and Ohtani, Shoichiro and Higaki, Kenji and Watanabe, Junichiro and Watanabe, Kenichi and Taguchi, Tetsuya and Taguchi, Kazunori and Takahashi, Masato and Filipovic, Sladjana and Hansen, Vincent L and Rao, Vijayarama Phooshkooru and Gupta, Manish and Petrov, Petar and Coudert, Bruno and Vojnovic, Zeljko and Polya, Zsofia and Miyaki, Toshiko and Yamamoto, Naohito and Brincat, Stephen and Lesniewski-Kmak, Krzysztof and Chmielowska, Ewa and ... and ExteNET Study Grp and ExteNET Study Group
The Lancet Oncology, ISSN 1470-2045, 12/2017, Volume 18, Issue 12, pp. 1688 - 1700
Journal Article